Here, we showed that streptonigrin has a very strong anti-RCC effect in vivo by inhibiting TGase 2 at very low concentrations (0.2 mg/kg); thus inhibition of TGase2 may be a novel and effective therapeutic approach. This evidence concerns the gene TGM2 and renal cell carcinoma.